Confo Therapeutics presented preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist targeting life-threatening hypoglycemic episodes in post-bariatric hypoglycemia (PBH). The company framed the program as a focused approach to PBH, a condition that can drive recurrent severe events after surgery. CFTX-2034 is built using Confo’s proprietary platform and is designed to modulate pathways relevant to glucose dysregulation in post-bariatric patients. The preclinical package adds to the evidence base ahead of potential human development. While the update was specifically preclinical, it reinforces continued investor and academic interest in mechanistically differentiated drugs for PBH where existing treatments can be limited. The data could also influence how PBH endpoints and translational biomarkers are selected for first-in-human studies.